Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


Articles published in Eur Radiol

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    April 2018
  1. GHAI S, Perlis N, Lindner U, Hlasny E, et al
    Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer - phase 1 trial.
    Eur Radiol. 2018 Apr 25. pii: 10.1007/s00330-018-5409.
    PubMed     Text format     Abstract available


  2. LOTTE R, Lafourcade A, Mozer P, Conort P, et al
    Multiparametric MRI for Suspected Recurrent Prostate Cancer after HIFU:Is DCE still needed?
    Eur Radiol. 2018 Apr 9. pii: 10.1007/s00330-018-5352.
    PubMed     Text format     Abstract available


  3. WINFIELD JM, Poillucci G, Blackledge MD, Collins DJ, et al
    Apparent diffusion coefficient of vertebral haemangiomas allows differentiation from malignant focal deposits in whole-body diffusion-weighted MRI.
    Eur Radiol. 2018;28:1687-1691.
    PubMed     Text format     Abstract available


  4. POLANEC SH, Lazar M, Wengert GJ, Bickel H, et al
    3D T2-weighted imaging to shorten multiparametric prostate MRI protocols.
    Eur Radiol. 2018;28:1634-1641.
    PubMed     Text format     Abstract available


    March 2018
  5. SHIN T, Kaji Y, Shukuya T, Nozaki M, et al
    Significant changes of T2 value in the peripheral zone and seminal vesicles after ejaculation.
    Eur Radiol. 2018;28:1009-1015.
    PubMed     Text format     Abstract available


    January 2018
  6. SELNAES KM, Kruger-Stokke B, Elschot M, Willoch F, et al
    (18)F-Fluciclovine PET/MRI for preoperative lymph node staging in high-risk prostate cancer patients.
    Eur Radiol. 2018 Jan 2. pii: 10.1007/s00330-017-5213.
    PubMed     Text format     Abstract available


  7. MEIER-SCHROERS M, Marx C, Schmeel FC, Wolter K, et al
    Revised PROPELLER for T2-weighted imaging of the prostate at 3 Tesla: impact on lesion detection and PI-RADS classification.
    Eur Radiol. 2018;28:24-30.
    PubMed     Text format     Abstract available


  8. ULLRICH T, Quentin M, Schmaltz AK, Arsov C, et al
    Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate.
    Eur Radiol. 2018;28:17-23.
    PubMed     Text format     Abstract available


  9. MARIOTTI GC, Falsarella PM, Garcia RG, Queiroz MRG, et al
    Incremental diagnostic value of targeted biopsy using mpMRI-TRUS fusion versus 14-fragments prostatic biopsy: a prospective controlled study.
    Eur Radiol. 2018;28:11-16.
    PubMed     Text format     Abstract available


    December 2017
  10. BREMBILLA G, Dell'Oglio P, Stabile A, Ambrosi A, et al
    Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection.
    Eur Radiol. 2017 Dec 21. pii: 10.1007/s00330-017-5229.
    PubMed     Text format     Abstract available


  11. BAUR ADJ, Schwabe J, Rogasch J, Maxeiner A, et al
    A direct comparison of contrast-enhanced ultrasound and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer detection and prediction of aggressiveness.
    Eur Radiol. 2017 Dec 13. pii: 10.1007/s00330-017-5192.
    PubMed     Text format     Abstract available


  12. BARRETT T, McLean M, Priest AN, Lawrence EM, et al
    Diagnostic evaluation of magnetization transfer and diffusion kurtosis imaging for prostate cancer detection in a re-biopsy population.
    Eur Radiol. 2017 Dec 8. pii: 10.1007/s00330-017-5169.
    PubMed     Text format     Abstract available


    October 2017
  13. REISAETER LAR, Futterer JJ, Losnegard A, Nygard Y, et al
    Optimising preoperative risk stratification tools for prostate cancer using mpMRI.
    Eur Radiol. 2017 Oct 6. doi: 10.1007/s00330-017-5031.
    PubMed     Text format     Abstract available


    September 2017
  14. IYAMA Y, Nakaura T, Katahira K, Iyama A, et al
    Development and validation of a logistic regression model to distinguish transition zone cancers from benign prostatic hyperplasia on multi-parametric prostate MRI.
    Eur Radiol. 2017;27:3600-3608.
    PubMed     Text format     Abstract available


    August 2017
  15. HAUSMANN D, Aksoz N, von Hardenberg J, Martini T, et al
    Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: Is a non-contrast protocol sufficient to detect significant cancer?
    Eur Radiol. 2017 Aug 10. doi: 10.1007/s00330-017-5004.
    PubMed     Text format     Abstract available


  16. JANSSEN JC, Meissner S, Woythal N, Prasad V, et al
    Comparison of hybrid 68Ga-PSMA-PET/CT and 99mTc-DPD-SPECT/CT for the detection of bone metastases in prostate cancer patients: Additional value of morphologic information from low dose CT.
    Eur Radiol. 2017 Aug 4. doi: 10.1007/s00330-017-4994.
    PubMed     Text format     Abstract available


  17. MUELLER-LISSE UG, Murer S, Mueller-Lisse UL, Kuhn M, et al
    Everyman's prostate phantom: kiwi-fruit substitute for human prostates at magnetic resonance imaging, diffusion-weighted imaging and magnetic resonance spectroscopy.
    Eur Radiol. 2017;27:3362-3371.
    PubMed     Text format     Abstract available


  18. OLSON MC, Atwell TD, Mynderse LA, King BF, et al
    CT-guided transgluteal biopsy for systematic sampling of the prostate in patients without rectal access: a 13-year single-center experience.
    Eur Radiol. 2017;27:3326-3332.
    PubMed     Text format     Abstract available


    July 2017
  19. PARK SY, Shin SJ, Jung DC, Cho NH, et al
    PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer.
    Eur Radiol. 2017;27:2776-2783.
    PubMed     Text format     Abstract available


    June 2017
  20. ZHANG L, Tang M, Chen S, Lei X, et al
    A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer.
    Eur Radiol. 2017 Jun 27. doi: 10.1007/s00330-017-4843.
    PubMed     Text format     Abstract available


  21. BATES A, Miles K
    Prostate-specific membrane antigen PET/MRI validation of MR textural analysis for detection of transition zone prostate cancer.
    Eur Radiol. 2017 Jun 12. doi: 10.1007/s00330-017-4877.
    PubMed     Text format     Abstract available


  22. HANSEN NL, Koo BC, Gallagher FA, Warren AY, et al
    Comparison of initial and tertiary centre second opinion reads of multiparametric magnetic resonance imaging of the prostate prior to repeat biopsy.
    Eur Radiol. 2017;27:2259-2266.
    PubMed     Text format     Abstract available


    May 2017
  23. GIGANTI F, Moore CM, Robertson NL, McCartan N, et al
    MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial.
    Eur Radiol. 2017 May 18. doi: 10.1007/s00330-017-4858.
    PubMed     Text format     Abstract available


  24. DE VISSCHERE PJ, Vral A, Perletti G, Pattyn E, et al
    Multiparametric magnetic resonance imaging characteristics of normal, benign and malignant conditions in the prostate.
    Eur Radiol. 2017;27:2095-2109.
    PubMed     Text format     Abstract available


  25. ROUVIERE O, Melodelima C, Hoang Dinh A, Bratan F, et al
    Stiffness of benign and malignant prostate tissue measured by shear-wave elastography: a preliminary study.
    Eur Radiol. 2017;27:1858-1866.
    PubMed     Text format     Abstract available


    April 2017
  26. OVERDUIN CG, Jenniskens SF, Sedelaar JP, Bomers JG, et al
    Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes.
    Eur Radiol. 2017 Apr 13. doi: 10.1007/s00330-017-4833.
    PubMed     Text format     Abstract available


  27. WANG J, Wu CJ, Bao ML, Zhang J, et al
    Machine learning-based analysis of MR radiomics can help to improve the diagnostic performance of PI-RADS v2 in clinically relevant prostate cancer.
    Eur Radiol. 2017 Apr 3. doi: 10.1007/s00330-017-4800.
    PubMed     Text format     Abstract available


  28. BOMERS JG, Bosboom DG, Tigelaar GH, Sabisch J, et al
    Feasibility of a 2nd generation MR-compatible manipulator for transrectal prostate biopsy guidance.
    Eur Radiol. 2017;27:1776-1782.
    PubMed     Text format     Abstract available


    December 2016
  29. WILDEBOER RR, Postema AW, Demi L, Kuenen MP, et al
    Multiparametric dynamic contrast-enhanced ultrasound imaging of prostate cancer.
    Eur Radiol. 2016 Dec 21. doi: 10.1007/s00330-016-4693.
    PubMed     Text format     Abstract available


  30. NKETIAH G, Elschot M, Kim E, Teruel JR, et al
    T2-weighted MRI-derived textural features reflect prostate cancer aggressiveness: preliminary results.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  31. SCHIMMOLLER L, Quentin M, Blondin D, Dietzel F, et al
    Targeted MRI-guided prostate biopsy: are two biopsy cores per MRI-lesion required?
    Eur Radiol. 2016;26:3858-3864.
    PubMed     Text format     Abstract available


    September 2016
  32. SIDHU HS, Benigno S, Ganeshan B, Dikaios N, et al
    "Textural analysis of multiparametric MRI detects transition zone prostate cancer".
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  33. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.
    Eur Radiol. 2016;26:2502-9.
    PubMed     Text format     Abstract available


    July 2016
  34. ROSSET R, Bratan F, Crouzet S, Tonoli-Catez H, et al
    Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer?
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


  35. VAN DEN BOS W, de Bruin DM, van Randen A, Engelbrecht MR, et al
    MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
    Eur Radiol. 2016;26:2252-60.
    PubMed     Text format     Abstract available


    June 2016
  36. BARBIERI S, Bronnimann M, Boxler S, Vermathen P, et al
    Differentiation of prostate cancer lesions with high and with low Gleason score by diffusion-weighted MRI.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


  37. MARTIN J, Arm J, Smart J, Palazzi K, et al
    Spinal multiparametric MRI and DEXA changes over time in men with prostate cancer treated with androgen deprivation therapy: a potential imaging biomarker of treatment toxicity.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  38. KIM CK, Park JJ, Park BK
    Prostate diffusion-weighted imaging at 3T: effect of intravenous gadobutrol administration.
    Eur Radiol. 2016;26:1450-6.
    PubMed     Text format     Abstract available


    April 2016
  39. DE VISSCHERE PJ, Naesens L, Libbrecht L, Van Praet C, et al
    What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging?
    Eur Radiol. 2016;26:1098-107.
    PubMed     Text format     Abstract available


    March 2016
  40. DERLIN T, Weiberg D, von Klot C, Wester HJ, et al
    Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  41. WOO S, Kim SY, Lee J, Kim SH, et al
    PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.
    Eur Radiol. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: